Evidence map›Paper›PMID 30016258›Full record

ArticleParasite (Paris, France)2018

High-dose ivermectin in malaria and other parasitic diseases: a new step in the development of a neglected drug.

Olivier Chosidow, Charlotte Bernigaud, Giao Do-Pham

Open access · goldAbstract readComment
In one paragraph

Article in Parasite (Paris, France), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Pathogens (Basel, Switzerland) · 2021
    Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Olivier ChosidowDepartment of Dermatology, Hôpital Henri-Mondor, AP-HP, Créteil, France - Research group EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques) EA 7379, Université Paris-Est Créteil Val-de-Marne, Créteil, France - French Satellite of the Cochrane Skin Group, Créteil, France.
Charlotte BernigaudDepartment of Dermatology, Hôpital Henri-Mondor, AP-HP, Créteil, France - Research Group Dynamyc, EA7380, Ecole nationale vétérinaire d'Alfort, Maisons-Alfort, Université Paris-Est Créteil, Créteil, France.
Giao Do-PhamDepartment of Internal Medicine, Centre Hospitalier Intercommunal de Créteil, Créteil, France.
Hôpital Intercommunal de Créteil · FRHôpitaux Universitaires Henri-Mondor · FRUniversité Paris-Est Créteil · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We highlight the absence of high-level evidence from dose-ranging studies regarding the use of oral ivermectin in susceptible parasitic diseases. We provide published data supporting the use of a higher dosage regimen of ivermectin in malaria and difficult-to-treat head lice, and announce an ongoing randomized clinical trial in severe scabies.

Indexed as

IvermectinMalariaScabiesAdministration, OralAnimalsArtemisininsDouble-Blind MethodHumansKenyaPiperazinesQuinolinesArtemisininsartenimolIvermectinpiperaquinePiperazinesQuinolines

Identifiers

PMID30016258
PMCPMC6050034
OpenAlexW2884267097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.